Cosmo Bio CompanyLimited Balance Sheet Health
Financial Health criteria checks 6/6
Cosmo Bio CompanyLimited has a total shareholder equity of ¥9.5B and total debt of ¥20.0M, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are ¥11.3B and ¥1.9B respectively. Cosmo Bio CompanyLimited's EBIT is ¥442.0M making its interest coverage ratio -7. It has cash and short-term investments of ¥3.0B.
Key information
0.2%
Debt to equity ratio
JP¥20.00m
Debt
| Interest coverage ratio | -7x |
| Cash | JP¥3.04b |
| Equity | JP¥9.48b |
| Total liabilities | JP¥1.85b |
| Total assets | JP¥11.33b |
Recent financial health updates
No updates
Recent updates
Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 12
Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital
May 09Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why
Mar 23Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?
Feb 07
Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?
Jan 17Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?
Dec 23Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?
Dec 02Financial Position Analysis
Short Term Liabilities: 3386's short term assets (¥7.1B) exceed its short term liabilities (¥908.0M).
Long Term Liabilities: 3386's short term assets (¥7.1B) exceed its long term liabilities (¥946.0M).
Debt to Equity History and Analysis
Debt Level: 3386 has more cash than its total debt.
Reducing Debt: 3386's debt to equity ratio has reduced from 0.3% to 0.2% over the past 5 years.
Debt Coverage: 3386's debt is well covered by operating cash flow (990%).
Interest Coverage: 3386 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:05 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cosmo Bio Company,Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|